In today s Research Roundup for December 21, 2023, we highlight some of the most interesting reads in global health research and development from the past week.
By Chris Wack Intellia Therapeutics shares were up 10% at $26.10 after the European Commission granted orphan drug designation to NTLA-2002 for the treatment.
Regulators in the United Kingdom have approved full marketing authorization for Maryland-based Novavax’s updated, protein-based COVID-19 booster shot, but regulators in the European Union have delayed a decision.
By Chris Wack Lisata Therapeutics shares were up 11% to $2.34 after the company said the European Medicines Agency Committee for Orphan Medicinal Products.
By Robb M. Stewart Bristol Myers Squibb said Friday that the European Medicines Agency Committee for Medicinal Products for Human Use has recommended approval of Opdivo in combination with. | May 26, 2023